AZAngela Zhou

Angela Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela Zhou has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthetic Control Analysis of the Short-Term Impact of New York State’s Bail Elimination Act on Aggregate Crime

    by Angela Zhou, Andrew Koo, Nathan Kallus, Rene Ropac, Richard Peterson, Stephen Koppel, Tiffany Bergin


  • Top Cited Papers

    Assessing Algorithmic Fairness with Unobserved Protected Class Using Data Combination

    by Nathan Kallus, Xiaojie Mao, Angela Zhou

    The increasing impact of algorithmic decisions on people’s lives compels us to scrutinize their fairness and, in particular, the disparate impacts that ostensibly color-blind algorithms can have on different groups. Examples include credit decisioning, hiring, advertising, criminal justice, personalized medicine, and targeted policy making, where in some cases legislative or regulatory frameworks for fairness exist and define specific protected classes. In this paper we study a fundamental challenge to assessing disparate impacts in practice: protected class membership is often not observed in the data. This is particularly a problem in lending and healthcare. We consider the use of an auxiliary data set, such as the U.S. census, to construct models that predict the protected class from proxy variables, such as surname and geolocation. We show that even with such data, a variety of common disparity measures are generally unidentifiable, providing a new perspective on the documented biases of popular proxy-based methods. We provide exact characterizations of the tightest possible set of all possible true disparities that are consistent with the data (and possibly additional assumptions). We further provide optimization-based algorithms for computing and visualizing these sets and statistical tools to assess sampling uncertainty. Together, these enable reliable and robust assessments of disparities—an important tool when disparity assessment can have far-reaching policy implications. We demonstrate this in two case studies with real data: mortgage lending and personalized medicine dosing. This paper was accepted by Hamid Nazerzadeh, Management Science Special Section on Data-Driven Prescriptive Analytics.


  • Minimax-Optimal Policy Learning Under Unobserved Confounding

    by Nathan Kallus, Angela Zhou

    We study the problem of learning personalized decision policies from observational data while accounting for possible unobserved confounding. Previous approaches, which assume unconfoundedness, that is, that no unobserved confounders affect both the treatment assignment as well as outcome, can lead to policies that introduce harm rather than benefit when some unobserved confounding is present as is generally the case with observational data. Instead, because policy value and regret may not be point-identifiable, we study a method that minimizes the worst-case estimated regret of a candidate policy against a baseline policy over an uncertainty set for propensity weights that controls the extent of unobserved confounding. We prove generalization guarantees that ensure our policy is safe when applied in practice and in fact obtains the best possible uniform control on the range of all possible population regrets that agree with the possible extent of confounding. We develop efficient algorithmic solutions to compute this minimax-optimal policy. Finally, we assess and compare our methods on synthetic and semisynthetic data. In particular, we consider a case study on personalizing hormone replacement therapy based on observational data, in which we validate our results on a randomized experiment. We demonstrate that hidden confounding can hinder existing policy-learning approaches and lead to unwarranted harm although our robust approach guarantees safety and focuses on well-evidenced improvement, a necessity for making personalized treatment policies learned from observational data reliable in practice. This paper was accepted by Hamid Nazerzadeh, big data analytics.


  • Open Access

    Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC

    by Derek L Clouthier, Angela C Zhou, Tania H Watts

    The costimulatory TNFR family member GITR can provide important survival signals for CD8 T cells. However, little is known about the regulation of this pathway during a chronic infection. In this study, we show that GITR ligand (GITRL) is maximally induced on APCs at day 2 post–lymphocytic choriomeningitis virus (LCMV) clone 13 infection, but is downregulated to below baseline levels by day 8 postinfection (p.i.), and remains so at the chronic stage of infection. At its peak, GITRL expression is highest on macrophages, with lower expression on conventional and plasmacytoid dendritic cells. GITR expression was highest on T regulatory cells but was also detected on Th1 and LCMV-specific CD8 T cells at day 8 p.i. and was maintained at low, but above baseline levels at the chronic stage of LCMV infection. As GITRL was limiting at the chronic stage of infection, we investigated the potential of therapeutic stimulation of GITR at this stage using agonistic anti-GITR Ab. Anti-GITR treatment at day 21 p.i. increased the frequency and number of LCMV-specific CD8 T cells, resulting in increased in vivo CTL activity and a concomitant decrease in viral load, despite the persistence of PD-1 expression. These effects of anti-GITR were CD8 T cell intrinsic, with no detectable effects on Th1 or T regulatory cells. In contrast to other TNFR agonists, such as anti–4-1BB, which can cause immune pathology, a single therapeutic dose of anti-GITR did not induce splenomegaly or increase serum alanine transaminase. These studies identify GITR as a promising therapeutic target for chronic infection.